Literature DB >> 21414809

Focal epilepsy as first symptom in CADASIL.

Reana Velizarova1, Isabelle Mourand, Anna Serafini, Arielle Crespel, Philippe Gelisse.   

Abstract

Recurrent transient ischemic attacks, migraine and dementia represent the principal symptoms of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). During the course of the disease, about 10% of patients may experience epileptic seizures, mainly related to the presence of an ischemic stroke. We present a 30-year-old woman with new-onset focal epilepsy leading to the diagnosis of CADASIL. The neuropsychological testing revealed no cognitive impairment. Interictal EEG demonstrated spikes and polyspikes with low amplitude over the right occipital region during NREM sleep. MRI showed white-matter hyperintensities on both hemispheres with confluent lesions at the right parieto-occipital junction, with juxtacortical components. Like in multiple sclerosis, we can suppose that this type of white matter lesions, close to the cortex, may be causative of seizures.
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414809     DOI: 10.1016/j.seizure.2011.02.006

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  A series of Notch3 mutations in CADASIL; insights from 3D molecular modelling and evolutionary analyses.

Authors:  Dimitrios Vlachakis; Spyridon Champeris Tsaniras; Katerina Ioannidou; Louis Papageorgiou; Marc Baumann; Sophia Kossida
Journal:  J Mol Biochem       Date:  2014

2.  CADASIL Initially Presented with a Seizure.

Authors:  Jung-Hwan Oh; Bong Su Kang; Jay Chol Choi
Journal:  J Epilepsy Res       Date:  2016-12-31

Review 3.  Recurrent generalized seizures as the prominent manifestation in a patient with CADASIL: a case report and literature review.

Authors:  Liuhua Pan; Yan Chen; Shanshan Zhao
Journal:  BMC Neurol       Date:  2022-09-30       Impact factor: 2.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.